Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Vimta Labs Ltd Stock Analysis

Small Cap
Evaluated by 574 users | BSE: 524394 | NSE: VIMTALABS |
Miscellaneous

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed -9.64%4.48%10.79%4.23%5.23%7.47%10.9%14.44%4.19%10.76%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 87.3109118107125154183213181209237
Y-o-Y Gr. Rt.-24.9%8.5%-9.3%16.3%23.4%19.2%15.9%-15%15.7%-
Adjusted EPS (Rs.) -7.41.735.382.192.884.957.5211.262.629.7614.13
Y-o-Y Gr. Rt.-NA211%-59.3%31.5%71.9%51.9%49.7%-76.7%272.5%-
Book Value per Share (Rs.) 49.650.8154.4555.3357.0461.5868.7777.5978.2387.8991.56
Adjusted Net Profit -16.43.811.94.86.410.916.624.95.821.631
Net Op. Cash Flow (Rs. Cr.) 12.915.516.815.3-123.933.439.324.437-
Debt to Cash Flow from Ops 1.590.750.390.23-25.611.821.20.661.330.8-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Vimta Labs Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 10.2%10.9%4.5%15.7%
Adjusted EPS NA27.7%9.1%272.5%
Book Value per Share 6.698.512.4
Share Price 31.7% 24.7% 1% 113.7%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) -13.953.4510.233.995.128.3411.5315.383.3711.7515.75
Operating Profit Margin (%) 1.1419.0222.0316.2315.1718.0724.8227.1716.6125.4227.67
Net Profit Margin (%) -18.733.5110.064.515.17.119.0611.713.2110.3213.15
Debt to Equity 0.190.10.050.030.210.320.260.150.190.15-
Working Capital Days 226166157187199187168158195186-
Cash Conversion Cycle 12878861121189992101128113-
Loading price chart...
Entity Percentage Holding
Promoters 37.46%
Institutions 0.11%
Non-Institutions 62.43%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Vimta Labs Ltd's earnings have grown by 27.7%, whereas share price has appreciated 24.7% CAGR over the past five years, indicating the company’s share price is likely undervalued. However, for specific investment actions please consult your investment advisor.

Vimta Labs Ltd share price has appreciated 31.7% annually (CAGR) over the past ten years.

Data is not available for this company.

Vimta Labs is India’s leading contract research and testing organization. Established in 1984, Vimta has an envious track record of serving several market leaders across the globe.

Vimta supports regulatory authorities in mandatory certification of food and agri products exported from India. Vimta assists the food industry commissions for nutritional labelling, food safety evaluations, trace analysis and shelf life studies.

Vimta has a team of 684 professionals comprising 446

Vimta Labs is India’s leading contract research and testing organization. Established in 1984, Vimta has an envious track record of serving several market leaders across the globe.

Vimta supports regulatory authorities in mandatory certification of food and agri products exported from India. Vimta assists the food industry commissions for nutritional labelling, food safety evaluations, trace analysis and shelf life studies.

Vimta has a team of 684 professionals comprising 446 scientists in various disciplines such as chemistry, pharma, medicine, microbiology, molecular biology and informatics. The team is slated to double in next three years.

Vimta is a multi-site organization with more than 300,000 sqft world class laboratory facilities. The technologies deployed at Vimta are current and leading edge, duly validated.

Vimta has over 12 years of experience in providing preclinical services to Pharma companies world-wide accordance with the guidelines prescribed by international agencies.

Vimta has a state-of-art building of Class 10,000 Pre-clinical facility with a total built up area of 33,000 sq.ft. with 32 rodent experimental rooms, 5 procedure rooms, separate quarantine facility and distinct non-rodent facility with 48 SS kennels with a comfortable perch, liberal exercise area.

It provides services in pharmacology, toxicology and DMPK areas. The toxicology services include but not limited to in-vivo and in-vitro genotoxicity, acute to chronic toxicity, carcinogenicity, reproductive toxicity studies, safety pharmacology, and immunotoxicology. Pharmacology services are available in various therapeutics areas such as pain & inflammation, metabolic disorders, respiratory, CNS, and xenograft & allograft models for oncology. In addition to the regulatory studies we use tailor-made in vitro and in vivo ADME techniques to help profile your drug candidate in both rodent and non-rodent animals models.

Services offered by the company:

  • Advanced Molecular Biology
  • Food and Agriculture
  • Drugs & Pharma
  • Water
  • Environmental Assessments
  • Clinical Research
  • Clinical Reference Lab Services
  • Preclinical Research
  • Genomics Online Ordering

 Achievements/ recognition

  •    NABL as per ISO 15189:2007
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback